This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0109v1 14/12/1242    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kobold, S. Articles by Atanackovic, D. Search for Related Content PubMed PubMed Citation Articles by Kobold, S. Articles by Atanackovic, D.

Symptom Management and Supportive Care

Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?

^aDepartment of Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ^bPrivate Oncology Practice, Hamburg, Germany; ^cClinic for Internal Medicine IV, Martin Luther University Halle-Wittenberg, Halle, Germany

Key Words. VEGF • Bevacizumab • Catumaxomab • Malignant ascites

Correspondence: Djordje Atanackovic, M.D., Department of Medicine II, Oncology/Hematology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Telephone: 49-40-7401-55032; Fax: 49-40-7401-55735; e-mail: D.Atanackovic{at}uke.uni-hamburg.de

Received June 12, 2009; accepted for publication November 8, 2009; first published online in THE ONCOLOGIST Express on December 11, 2009.

Disclosures: Sebastian Kobold: None; Susanna Hegewisch-Becker: None; Karin Oechsle: None; Karin Jordan: None; Carsten Bokemeyer: Research funding/contracted research: Fresenius Biotech; Djordje Atanackovic: None.

This article discusses bevacizumab (Genentech) for intraperitoneal use.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Despite overall improvements in oncological care in the palliative setting, symptomatic malignant ascites remains a severe clinical problem. This form of effusion is known to be widely resistant to established modes of systemic therapy. Accordingly, frequent paracentesis often represents the only effective way for symptom relief in patients with advanced cancer. This invasive mode of therapy, however, is often very burdensome for the patient who is already severely distressed by the underlying malignancy. Recently, the trifunctional monoclonal antibody catumaxomab given i.p. has shown symptom relief in patients with ovarian cancer and malignant ascites. On another front, the release of vascular endothelial growth factor (VEGF) by tumor cells has been identified as a main factor promoting the i.p. secretion of fluid. Accordingly, recent evidence suggests that targeting VEGF may have the potential to suspend the ascites production resulting from peritoneal metastasis. Here, we review preclinical and clinical data supporting this hypothesis. We show current evidence suggesting that the i.p. application of the anti-VEGF antibody bevacizumab, which is already in use as an i.v. therapeutic drug for a variety of tumors, might represent an effective way to prevent local fluid accumulation. Because such an effect would result in significant relief for patients, future clinical studies should stringently assess the effectiveness of this targeted therapy for the treatment of malignant i.p. effusions.